Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in childre...
Saved in:
| Published in | The lancet oncology Vol. 14; no. 6; pp. 472 - 480 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.05.2013
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1470-2045 1474-5488 1474-5488 |
| DOI | 10.1016/S1470-2045(13)70095-0 |
Cover
| Abstract | Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma.
In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m2 per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials.gov, NCT00939770.
79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10·1 years (range 1·1–21·4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m2 twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1–6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC).
The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring known ALK oncogenic mutations is warranted.
Pfizer and National Cancer Institute grant to the Children's Oncology Group. |
|---|---|
| AbstractList | Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma.
In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m(2) per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials.gov, NCT00939770.
79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10.1 years (range 1.1-21.4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m(2) twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1-6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC).
The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring known ALK oncogenic mutations is warranted.
Pfizer and National Cancer Institute grant to the Children's Oncology Group. Summary Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma. Methods In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m2 per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials.gov , NCT00939770. Findings 79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10·1 years (range 1·1–21·4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m2 twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1–6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC). Interpretation The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring known ALK oncogenic mutations is warranted. Funding Pfizer and National Cancer Institute grant to the Children's Oncology Group. Background: Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma. Methods: In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m super(2) per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials.gov, NCT00939770. Findings: 79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10.1 years (range 1.1-21.4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m super(2) twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1-6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC). Interpretation: The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring known ALK oncogenic mutations is warranted. Funding Pfizer and National Cancer Institute grant to the Children's Oncology Group. Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma. In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m2 per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials.gov, NCT00939770. 79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10·1 years (range 1·1–21·4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m2 twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1–6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC). The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring known ALK oncogenic mutations is warranted. Pfizer and National Cancer Institute grant to the Children's Oncology Group. Various human cancers haveALKgene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma. Methods In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m2per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmedALKtranslocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessedALKgenomic status in tumour tissue and used quantitative RT-PCR to measureNPM-ALKfusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered withClinicalTrials.gov,NCT00939770. Findings 79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10·1 years (range 1·1-21·4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m2twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1-6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activatingALKaberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC). Interpretation The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouringALKtranslocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring knownALKoncogenic mutations is warranted. Funding Pfizer and National Cancer Institute grant to the Children's Oncology Group. Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma. Methods: In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m2 per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials.gov, NCT00939770. Findings: 79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10ADT1 years (range 1ADT1a21ADT4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m2 twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1a6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC). Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma.BACKGROUNDVarious human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma.In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m(2) per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials.gov, NCT00939770.METHODSIn this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m(2) per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials.gov, NCT00939770.79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10.1 years (range 1.1-21.4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m(2) twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1-6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC).FINDINGS79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10.1 years (range 1.1-21.4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m(2) twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1-6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC).The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring known ALK oncogenic mutations is warranted.INTERPRETATIONThe findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring known ALK oncogenic mutations is warranted.Pfizer and National Cancer Institute grant to the Children's Oncology Group.FUNDINGPfizer and National Cancer Institute grant to the Children's Oncology Group. |
| Author | Lim, Megan S Laliberte, Julie Adamson, Peter C Maris, John M Mossé, Yael P Blaney, Susan M Ruffner, Katherine Balis, Frank M Rolland, Delphine Ahern, Charlotte Voss, Stephan D Ingle, Ashish M Weigel, Brenda J Wilner, Keith |
| Author_xml | – sequence: 1 givenname: Yael P surname: Mossé fullname: Mossé, Yael P email: mosse@chop.edu organization: Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA – sequence: 2 givenname: Megan S surname: Lim fullname: Lim, Megan S organization: Department of Pathology, University of Michigan, Ann Arbor, MI, USA – sequence: 3 givenname: Stephan D surname: Voss fullname: Voss, Stephan D organization: Department of Radiology, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA – sequence: 4 givenname: Keith surname: Wilner fullname: Wilner, Keith organization: Pfizer Oncology, La Jolla, CA, USA – sequence: 5 givenname: Katherine surname: Ruffner fullname: Ruffner, Katherine organization: Pfizer Oncology, La Jolla, CA, USA – sequence: 6 givenname: Julie surname: Laliberte fullname: Laliberte, Julie organization: Department of Pathology, University of Michigan, Ann Arbor, MI, USA – sequence: 7 givenname: Delphine surname: Rolland fullname: Rolland, Delphine organization: Department of Pathology, University of Michigan, Ann Arbor, MI, USA – sequence: 8 givenname: Frank M surname: Balis fullname: Balis, Frank M organization: Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA – sequence: 9 givenname: John M surname: Maris fullname: Maris, John M organization: Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA – sequence: 10 givenname: Brenda J surname: Weigel fullname: Weigel, Brenda J organization: Division of Pediatric Oncology, University of Minnesota Cancer Center, Minneapolis, MN, USA – sequence: 11 givenname: Ashish M surname: Ingle fullname: Ingle, Ashish M organization: Children's Oncology Group Operations Center, Monrovia, CA, USA – sequence: 12 givenname: Charlotte surname: Ahern fullname: Ahern, Charlotte organization: Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA – sequence: 13 givenname: Peter C surname: Adamson fullname: Adamson, Peter C organization: Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA – sequence: 14 givenname: Susan M surname: Blaney fullname: Blaney, Susan M organization: Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23598171$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl2P1CAUhhuzxv3Qn6Ah8cL1ogoUWqpxjZnoarLJXqxeE0rpDCuFCnRM_VP-RenMrh-TmNkroLzvQ88573F2YJ1VWfYYwRcIovLlFSIVzDEk9BQVzysIa5rDe9lR-kxyShg72Oy3ksPsOIRrCFGFIH2QHeKC1iwdjrKfV6JTcQLCtkDIqNc6HVwHpNc_XNRWN6BzHgxCtVpEr2XaRq1sDOC7jivgVeeTz_kJBGd0C-LYu9EHkEzCisGIEJPJCL9UuVTGADP1w8r14hUQYLHSpvXKPgvg0kpn3HIC596NAxhWIiiAgHQ2OB_12IMQx3Z6mN3vhAnq0c16kn358P7z4mN-cXn-afHuIpdlBWMuRU2bmhaSUcTKsqkbTLsW4440qqmURA0uGYENqwTChDVVwXDVCVJ3da2qhhUn2dmWO4xNr1qZKvbC8MHrXviJO6H5vzdWr_jSrXlRFZChGXB6A_Du26hC5L0OcwOEVW4MHFUUYcwwhneTIsJKvF9aEEYhQbRI0qc70us0GJuaNqvKGpEUgaR68nedvwu8TUgSvN4KpHchpHFzqWOKgJvL1oYjyOc88k0e-Ry2hOebPPK5NLrjvn1gn-_t1qfSjNdaeR5kSp1MKfRKRt46vZdwtkOQJsVZCvNVTSr86QUPmMMtZGagYkOYAW_-D7jDD_wCTawiXQ |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1097_MPH_0000000000001326 crossref_primary_10_1111_bjh_15789 crossref_primary_10_1371_journal_pone_0132330 crossref_primary_10_1016_j_cancergen_2013_07_001 crossref_primary_10_3390_jpm11050395 crossref_primary_10_1007_s40272_017_0251_3 crossref_primary_10_18632_oncotarget_1883 crossref_primary_10_1007_s12253_017_0332_1 crossref_primary_10_3390_cancers15204940 crossref_primary_10_1080_28354311_2024_2385849 crossref_primary_10_1097_MPH_0000000000000353 crossref_primary_10_1634_theoncologist_2019_0615 crossref_primary_10_1016_j_ejca_2021_08_022 crossref_primary_10_1097_MPH_0000000000000594 crossref_primary_10_59717_j_xinn_med_2024_100048 crossref_primary_10_1016_j_molmet_2023_101771 crossref_primary_10_1097_MOP_0000000000000570 crossref_primary_10_1038_s41388_021_02018_7 crossref_primary_10_3390_pharmaceutics13091427 crossref_primary_10_1002_pbc_27035 crossref_primary_10_1038_s41591_023_02297_5 crossref_primary_10_3390_healthcare10040692 crossref_primary_10_1016_j_bulcan_2022_12_011 crossref_primary_10_1053_j_sempedsurg_2016_09_007 crossref_primary_10_1097_MPH_0000000000002304 crossref_primary_10_1007_s00441_017_2784_8 crossref_primary_10_1111_bjh_15775 crossref_primary_10_1158_0008_5472_CAN_14_3817 crossref_primary_10_32604_or_2024_050350 crossref_primary_10_1186_s12943_022_01583_z crossref_primary_10_1111_ejh_12360 crossref_primary_10_1126_scisignal_aar5680 crossref_primary_10_1002_pbc_28473 crossref_primary_10_1124_mol_120_119495 crossref_primary_10_1101_mcs_a006064 crossref_primary_10_1093_bmb_ldt033 crossref_primary_10_3390_cancers14205022 crossref_primary_10_3389_fonc_2021_658327 crossref_primary_10_3390_cancers15030560 crossref_primary_10_1038_s41467_020_18987_4 crossref_primary_10_1200_JCO_2014_59_4648 crossref_primary_10_1182_bloodadvances_2017008748 crossref_primary_10_1158_2159_8290_CD_22_0287 crossref_primary_10_18632_oncotarget_8173 crossref_primary_10_1097_PAS_0000000000000330 crossref_primary_10_3389_fonc_2023_1122508 crossref_primary_10_1097_MOP_0000000000001201 crossref_primary_10_3390_cancers14071650 crossref_primary_10_1371_journal_pone_0122555 crossref_primary_10_1038_pr_2017_74 crossref_primary_10_1093_jnci_djt378 crossref_primary_10_1002_gcc_23097 crossref_primary_10_1002_pbc_27012 crossref_primary_10_1002_pbc_26288 crossref_primary_10_1200_PO_21_00078 crossref_primary_10_1007_s40272_017_0265_x crossref_primary_10_3390_cancers16162865 crossref_primary_10_1093_annonc_mdw301 crossref_primary_10_7759_cureus_27223 crossref_primary_10_1007_s40272_020_00380_9 crossref_primary_10_3390_jpm12020267 crossref_primary_10_1097_PAP_0000000000000164 crossref_primary_10_1016_j_taap_2019_114781 crossref_primary_10_1200_JCO_21_00086 crossref_primary_10_1016_j_ejca_2017_06_026 crossref_primary_10_3390_cancers10040114 crossref_primary_10_3390_cancers10040113 crossref_primary_10_1111_ped_14117 crossref_primary_10_1002_pbc_27003 crossref_primary_10_1016_j_leukres_2019_05_014 crossref_primary_10_3324_haematol_2021_280081 crossref_primary_10_1080_2162402X_2017_1373232 crossref_primary_10_1002_ijc_30533 crossref_primary_10_1016_j_jocn_2015_08_017 crossref_primary_10_1002_ajh_25513 crossref_primary_10_1200_PO_18_00297 crossref_primary_10_1007_s10637_019_00802_7 crossref_primary_10_1016_j_epsc_2016_08_006 crossref_primary_10_18632_oncotarget_2648 crossref_primary_10_3389_fonc_2020_585830 crossref_primary_10_1038_s41571_019_0179_3 crossref_primary_10_1111_joim_13709 crossref_primary_10_1016_j_pcl_2014_09_015 crossref_primary_10_1038_509S55a crossref_primary_10_1111_his_12619 crossref_primary_10_1111_joim_13717 crossref_primary_10_1684_bdc_2014_1904 crossref_primary_10_3109_08880018_2013_816810 crossref_primary_10_1038_s41698_023_00449_x crossref_primary_10_1517_14728222_2014_867946 crossref_primary_10_3390_ijms19123784 crossref_primary_10_1097_PPO_0000000000000016 crossref_primary_10_1186_s12943_018_0776_2 crossref_primary_10_1002_hed_23884 crossref_primary_10_3390_ijms19030739 crossref_primary_10_1097_PG9_0000000000000019 crossref_primary_10_1097_PPO_0000000000000142 crossref_primary_10_1021_acs_jproteome_4c00554 crossref_primary_10_1016_j_ctrv_2024_102793 crossref_primary_10_1002_pbc_26137 crossref_primary_10_1002_pbc_26258 crossref_primary_10_1038_clpt_2013_200 crossref_primary_10_1371_journal_pone_0141381 crossref_primary_10_1517_17425255_2015_1021685 crossref_primary_10_1007_s00432_014_1589_3 crossref_primary_10_1186_s13045_015_0160_2 crossref_primary_10_1016_j_critrevonc_2015_12_016 crossref_primary_10_3324_haematol_2022_281896 crossref_primary_10_1002_cam4_5479 crossref_primary_10_1016_S2352_4642_22_00344_3 crossref_primary_10_3390_pharmaceutics14122834 crossref_primary_10_3390_cancers8010013 crossref_primary_10_1002_ccr3_2543 crossref_primary_10_1200_JCO_2017_74_4144 crossref_primary_10_1002_pbc_26365 crossref_primary_10_3390_pharmaceutics15020664 crossref_primary_10_1371_journal_pone_0224227 crossref_primary_10_3389_fonc_2019_00579 crossref_primary_10_1200_JCO_2014_59_5827 crossref_primary_10_1016_j_pcl_2014_09_018 crossref_primary_10_3389_fped_2021_652583 crossref_primary_10_18632_oncotarget_4501 crossref_primary_10_1002_cam4_414 crossref_primary_10_1182_asheducation_2015_1_522 crossref_primary_10_1001_jamadermatol_2021_0025 crossref_primary_10_1093_jjco_hyx176 crossref_primary_10_2217_fon_2020_1052 crossref_primary_10_3389_fonc_2021_669667 crossref_primary_10_1158_2159_8290_CD_15_1056 crossref_primary_10_3390_cancers15174252 crossref_primary_10_1182_asheducation_2015_1_550 crossref_primary_10_1158_1535_7163_MCT_21_0126 crossref_primary_10_1038_s41416_020_0770_5 crossref_primary_10_1038_s41420_018_0059_0 crossref_primary_10_1097_MPH_0000000000002137 crossref_primary_10_1016_j_ejca_2022_01_033 crossref_primary_10_1038_nm_4204 crossref_primary_10_1200_JCO_2017_73_4830 crossref_primary_10_1016_S1470_2045_15_00233_8 crossref_primary_10_59717_j_xinn_med_2023_100048 crossref_primary_10_1007_s11912_017_0582_9 crossref_primary_10_7759_cureus_16882 crossref_primary_10_1177_1066896915606971 crossref_primary_10_17650_1818_8346_2023_18_2_35_44 crossref_primary_10_1200_JCO_2013_53_7076 crossref_primary_10_1053_j_seminhematol_2013_11_001 crossref_primary_10_12998_wjcc_v9_i17_4268 crossref_primary_10_1245_s10434_015_4848_x crossref_primary_10_1016_j_ejca_2024_114201 crossref_primary_10_1038_onc_2015_519 crossref_primary_10_1371_journal_pone_0106575 crossref_primary_10_3389_fonc_2014_00201 crossref_primary_10_1126_science_aat6768 crossref_primary_10_3390_cancers15205089 crossref_primary_10_1097_PPO_0000000000000345 crossref_primary_10_14694_EdBook_AM_2015_35_e601 crossref_primary_10_1038_nrclinonc_2016_31 crossref_primary_10_1038_s41598_017_17319_9 crossref_primary_10_1016_S2213_2600_18_30116_4 crossref_primary_10_1080_14728214_2017_1294159 crossref_primary_10_1016_j_omtn_2017_01_005 crossref_primary_10_2478_ahp_2019_0010 crossref_primary_10_1186_s40348_018_0084_3 crossref_primary_10_1517_14656566_2015_1074176 crossref_primary_10_1158_2767_9764_CRC_23_0234 crossref_primary_10_1038_s41388_022_02489_2 crossref_primary_10_3390_children5110148 crossref_primary_10_1111_bjh_12777 crossref_primary_10_21682_2311_1267_2020_7_2_64_77 crossref_primary_10_2217_ijh_14_31 crossref_primary_10_18632_oncotarget_6393 crossref_primary_10_1080_17460441_2017_1340269 crossref_primary_10_1002_pbc_27094 crossref_primary_10_1016_j_anpede_2016_05_002 crossref_primary_10_1080_13543784_2017_1380625 crossref_primary_10_1016_j_anpedi_2016_05_006 crossref_primary_10_1111_cas_13333 crossref_primary_10_1038_s41598_018_37240_z crossref_primary_10_1055_s_0042_1758353 crossref_primary_10_1038_s41698_022_00256_w crossref_primary_10_1158_0008_5472_CAN_15_1308 crossref_primary_10_1111_bpa_12326 crossref_primary_10_1080_2162402X_2015_1016704 crossref_primary_10_18632_oncotarget_27119 crossref_primary_10_2217_fon_13_184 crossref_primary_10_3390_vaccines9010043 crossref_primary_10_1182_blood_2021011572 crossref_primary_10_1164_rccm_201702_0405CP crossref_primary_10_1053_j_seminoncol_2020_02_005 crossref_primary_10_1038_onc_2017_128 crossref_primary_10_1016_j_oncohp_2015_04_001 crossref_primary_10_1038_nrclinonc_2017_127 crossref_primary_10_1136_jclinpath_2016_204244 crossref_primary_10_1016_j_canlet_2019_02_002 crossref_primary_10_1016_j_coph_2015_05_010 crossref_primary_10_1038_s41388_018_0397_7 crossref_primary_10_1126_scisignal_2005470 crossref_primary_10_1016_j_tranon_2017_04_008 crossref_primary_10_1007_s12098_017_2318_0 crossref_primary_10_3390_cancers14122912 crossref_primary_10_1016_j_bbcan_2014_02_005 crossref_primary_10_1126_scitranslmed_aau9732 crossref_primary_10_1158_1078_0432_CCR_15_0379 crossref_primary_10_14712_fb2024070030123 crossref_primary_10_3322_caac_21665 crossref_primary_10_1016_j_beha_2023_101444 crossref_primary_10_1242_dmm_024448 crossref_primary_10_1016_j_beha_2023_101443 crossref_primary_10_1016_j_ccell_2023_11_004 crossref_primary_10_1200_JCO_24_02407 crossref_primary_10_3389_fonc_2022_1085270 crossref_primary_10_1038_leu_2014_166 crossref_primary_10_3389_fonc_2021_785855 crossref_primary_10_2217_pgs_2016_0166 crossref_primary_10_1200_EDBK_159169 crossref_primary_10_1080_14656566_2021_1953470 crossref_primary_10_1002_pbc_27073 crossref_primary_10_5863_1551_6776_26_6_647 crossref_primary_10_17925_OHR_2018_14_1_21 crossref_primary_10_1158_1078_0432_CCR_17_0381 crossref_primary_10_1016_j_ejca_2019_12_021 crossref_primary_10_1371_journal_pone_0082513 crossref_primary_10_2217_fon_16_15 crossref_primary_10_3390_cancers13010144 crossref_primary_10_3390_cancers9090123 crossref_primary_10_1158_2159_8290_CD_14_0377 crossref_primary_10_1111_cas_14671 crossref_primary_10_1016_j_anpedi_2016_07_007 crossref_primary_10_1016_j_soc_2023_12_008 crossref_primary_10_1111_bjh_13958 crossref_primary_10_1182_asheducation_2016_1_589 crossref_primary_10_2342_ymj_71_103 crossref_primary_10_1097_MPH_0000000000000498 crossref_primary_10_1016_j_oncohp_2014_01_004 crossref_primary_10_1016_j_ajpath_2015_10_016 crossref_primary_10_1007_s12561_019_09264_0 crossref_primary_10_1016_j_therap_2020_02_010 crossref_primary_10_1200_JCO_20_00157 crossref_primary_10_1038_nbt_2924 crossref_primary_10_1002_cnr2_1616 crossref_primary_10_1002_pbc_27055 crossref_primary_10_1002_cncr_29706 crossref_primary_10_1200_JCO_22_02430 crossref_primary_10_1016_j_bmc_2022_117043 crossref_primary_10_1182_blood_2016_05_717793 crossref_primary_10_1186_s13104_015_1277_7 crossref_primary_10_1200_JCO_22_00272 crossref_primary_10_1111_cas_14206 crossref_primary_10_1038_s41388_018_0595_3 crossref_primary_10_1111_his_12910 crossref_primary_10_1182_blood_2020008136 crossref_primary_10_1038_s41379_021_00830_w crossref_primary_10_1016_j_soc_2019_08_005 crossref_primary_10_1038_s41467_023_38195_0 crossref_primary_10_3390_children5100142 crossref_primary_10_1002_pbc_29346 crossref_primary_10_1007_s13193_015_0417_9 crossref_primary_10_1155_2018_3413592 crossref_primary_10_1371_journal_pcbi_1012648 crossref_primary_10_18632_oncotarget_6778 crossref_primary_10_1002_pbc_28916 crossref_primary_10_1038_s41379_019_0406_6 crossref_primary_10_1097_PAT_0000000000000277 crossref_primary_10_1016_j_gde_2017_03_008 crossref_primary_10_1016_S1470_2045_17_30337_6 crossref_primary_10_21682_2311_1267_2019_6_2_54_60 crossref_primary_10_1002_jcph_1359 crossref_primary_10_4155_cli_13_90 crossref_primary_10_1038_nrclinonc_2014_26 crossref_primary_10_1016_j_neo_2024_100964 crossref_primary_10_1038_s41568_018_0003_x crossref_primary_10_1111_febs_12453 crossref_primary_10_1186_s13046_021_01967_x crossref_primary_10_1080_10543406_2022_2149770 crossref_primary_10_1007_s00247_015_3360_6 crossref_primary_10_1080_10428194_2020_1839658 crossref_primary_10_1182_asheducation_V2015_1_522_3916185 crossref_primary_10_1038_s41698_023_00386_9 crossref_primary_10_1097_PAS_0000000000000909 crossref_primary_10_1097_JTO_0000000000000403 crossref_primary_10_1002_ijc_29077 crossref_primary_10_1111_petr_13210 crossref_primary_10_1038_s41598_019_55060_7 crossref_primary_10_3389_fonc_2021_709525 crossref_primary_10_1007_s12185_014_1522_1 crossref_primary_10_1056_NEJMc1511045 crossref_primary_10_1038_bmt_2015_57 crossref_primary_10_3892_ol_2019_9985 crossref_primary_10_1517_17460441_2015_1025745 crossref_primary_10_1038_s41418_018_0080_0 crossref_primary_10_1080_2162402X_2015_1087637 crossref_primary_10_1016_j_anpede_2016_07_007 crossref_primary_10_1038_cddis_2015_102 crossref_primary_10_1007_s12288_017_0889_6 crossref_primary_10_1016_j_phrs_2018_02_023 crossref_primary_10_3390_cancers13174360 crossref_primary_10_1200_PO_20_00181 crossref_primary_10_1016_j_path_2020_08_002 crossref_primary_10_3390_cancers12102989 crossref_primary_10_1200_JCO_2013_54_0674 crossref_primary_10_1007_s12035_024_04680_w crossref_primary_10_3109_10428194_2015_1055484 crossref_primary_10_1186_s13045_020_01006_w crossref_primary_10_1038_s41375_023_02038_0 crossref_primary_10_1007_s11864_021_00898_1 crossref_primary_10_1016_j_medj_2024_11_003 crossref_primary_10_1038_nrdp_2016_78 crossref_primary_10_18632_oncotarget_17033 crossref_primary_10_1097_MD_0000000000008974 crossref_primary_10_1158_1541_7786_MCR_18_0171 crossref_primary_10_1200_JCO_2014_55_6571 crossref_primary_10_1038_s41568_025_00797_9 crossref_primary_10_1016_j_bmc_2022_117071 crossref_primary_10_1021_acs_jproteome_6b00457 crossref_primary_10_1016_j_canlet_2020_08_014 crossref_primary_10_1158_2159_8290_CD_15_1411 crossref_primary_10_1002_med_21750 crossref_primary_10_1007_s10637_019_00742_2 crossref_primary_10_1038_s41467_019_12187_5 crossref_primary_10_1002_1878_0261_12088 crossref_primary_10_1158_2767_9764_CRC_24_0338 crossref_primary_10_12936_tenrikiyo_16_020 crossref_primary_10_17816_onco40081 crossref_primary_10_1158_1078_0432_CCR_14_2791 crossref_primary_10_1016_j_ccell_2014_09_019 crossref_primary_10_1158_1078_0432_CCR_14_1100 crossref_primary_10_1371_journal_pone_0210994 crossref_primary_10_1016_j_bbacli_2014_06_003 crossref_primary_10_1158_1078_0432_CCR_14_2314 crossref_primary_10_15252_embj_2020105784 crossref_primary_10_1016_j_jmoldx_2020_07_006 crossref_primary_10_1517_21678707_2015_1086334 crossref_primary_10_1097_PAS_0000000000001083 crossref_primary_10_18632_oncotarget_8508 crossref_primary_10_1182_blood_2017_07_798157 crossref_primary_10_1371_journal_pone_0092147 crossref_primary_10_3390_cancers12102951 crossref_primary_10_3390_cancers13143531 crossref_primary_10_1038_srep33710 crossref_primary_10_1002_ajh_26270 crossref_primary_10_1158_1078_0432_CCR_20_4224 crossref_primary_10_1097_MPH_0000000000002185 crossref_primary_10_1111_cts_13515 crossref_primary_10_1038_bcj_2016_52 crossref_primary_10_1002_pbc_24991 crossref_primary_10_1093_cercor_bhab058 crossref_primary_10_3390_cancers10040099 crossref_primary_10_1007_s13312_020_1849_z crossref_primary_10_1038_ng_3333 crossref_primary_10_1093_jnci_djw274 crossref_primary_10_1158_0008_5472_CAN_16_2550 crossref_primary_10_1002_cam4_2647 crossref_primary_10_1158_0008_5472_CAN_16_1106 crossref_primary_10_3390_cancers10030062 crossref_primary_10_1111_bjh_14074 crossref_primary_10_12936_tenrikiyo_26_002 crossref_primary_10_1158_0008_5472_CAN_14_3437 crossref_primary_10_24953_turkjpediatr_2025_5463 crossref_primary_10_1038_s41416_023_02208_y crossref_primary_10_1038_s41419_017_0060_1 crossref_primary_10_1158_1078_0432_CCR_21_0627 crossref_primary_10_1016_j_ejca_2023_112984 crossref_primary_10_18632_oncotarget_12513 crossref_primary_10_4103_ijc_IJC_240_20 crossref_primary_10_1177_1078155219852670 crossref_primary_10_3390_ijms222312883 crossref_primary_10_1002_pbc_26920 crossref_primary_10_1038_ng_3366 crossref_primary_10_1007_s00280_024_04678_0 crossref_primary_10_18632_oncotarget_22423 crossref_primary_10_1186_s13073_024_01297_5 crossref_primary_10_1002_ajh_25043 crossref_primary_10_1038_s41375_021_01191_8 crossref_primary_10_1093_ckj_sfac062 crossref_primary_10_1080_14737140_2017_1285230 crossref_primary_10_1586_17474086_2016_1122514 crossref_primary_10_1002_cpt_90 crossref_primary_10_17116_terarkh201789751_56 crossref_primary_10_1002_pbc_30172 crossref_primary_10_1126_scisignal_aap9752 crossref_primary_10_1002_1878_0261_12069 crossref_primary_10_1186_s13256_016_0963_y crossref_primary_10_1158_1078_0432_CCR_13_0680 crossref_primary_10_1007_s11912_025_01650_w crossref_primary_10_3390_ijms222112089 crossref_primary_10_21682_2311_1267_2021_8_4_71_80 crossref_primary_10_1007_s00441_018_2821_2 crossref_primary_10_1080_21678707_2017_1304212 crossref_primary_10_1016_j_currproblcancer_2017_01_002 crossref_primary_10_1101_mcs_a002550 crossref_primary_10_1097_MOP_0000000000000054 crossref_primary_10_1097_PAS_0000000000000753 crossref_primary_10_1097_MOP_0000000000000172 crossref_primary_10_3390_children5090114 crossref_primary_10_1016_j_ejphar_2022_175030 crossref_primary_10_1200_PO_21_00451 crossref_primary_10_1007_s00280_020_04171_4 crossref_primary_10_1172_JCI78488 crossref_primary_10_1016_j_jpedsurg_2018_09_004 crossref_primary_10_1111_apm_12940 crossref_primary_10_3389_fonc_2023_1176790 crossref_primary_10_1038_s41388_017_0039_5 crossref_primary_10_3389_fonc_2022_761558 crossref_primary_10_1002_gcc_22199 crossref_primary_10_1111_ejh_12404 crossref_primary_10_1080_08880018_2021_1907493 crossref_primary_10_3390_cancers9110148 crossref_primary_10_1517_21678707_2016_1120663 crossref_primary_10_1080_15384047_2015_1095407 crossref_primary_10_1038_s41392_024_01760_0 crossref_primary_10_1177_0300060516676725 crossref_primary_10_18632_oncotarget_4999 crossref_primary_10_1002_pbc_29602 crossref_primary_10_1016_j_tranon_2021_101150 crossref_primary_10_1051_medsci_20153110010 crossref_primary_10_3390_publications12040045 crossref_primary_10_3390_diagnostics11030512 crossref_primary_10_3390_cells8020103 crossref_primary_10_1038_srep19423 crossref_primary_10_1007_s00441_018_2820_3 crossref_primary_10_1007_s10555_020_09843_4 crossref_primary_10_1200_PO_18_00396 crossref_primary_10_1038_nrc3580 crossref_primary_10_1002_cnr2_1377 crossref_primary_10_7554_eLife_17137 crossref_primary_10_1158_0008_5472_CAN_14_0241 crossref_primary_10_3390_biom13101490 crossref_primary_10_1016_j_critrevonc_2016_10_001 crossref_primary_10_3390_cancers9120161 crossref_primary_10_1038_modpathol_2014_165 crossref_primary_10_1002_pbc_27771 crossref_primary_10_1002_pbc_26565 crossref_primary_10_1038_s41416_020_0996_2 crossref_primary_10_1158_1535_7163_MCT_17_0868 crossref_primary_10_12936_tenrikiyo_23_001 crossref_primary_10_1136_wjps_2020_000164 crossref_primary_10_4081_rt_2016_6266 crossref_primary_10_1016_j_oncohp_2013_05_006 crossref_primary_10_1159_000360212 crossref_primary_10_1002_pbc_25345 crossref_primary_10_3390_cancers13081907 crossref_primary_10_3390_cancers15051418 crossref_primary_10_1093_annonc_mdw030 crossref_primary_10_1111_bjh_13167 crossref_primary_10_1182_blood_2014_10_567461 crossref_primary_10_1111_jpc_14809 crossref_primary_10_1126_scisignal_2005940 crossref_primary_10_1158_1078_0432_CCR_16_1114 crossref_primary_10_1186_s12864_021_08094_z crossref_primary_10_1007_s12185_014_1701_0 crossref_primary_10_1016_S1470_2045_21_00536_2 crossref_primary_10_18632_oncotarget_2372 crossref_primary_10_1016_j_chest_2023_05_035 crossref_primary_10_1080_10428194_2018_1562182 crossref_primary_10_1158_1078_0432_CCR_21_3716 crossref_primary_10_1371_journal_pone_0123542 crossref_primary_10_1586_14737140_2014_974564 crossref_primary_10_1007_s00595_019_01790_0 crossref_primary_10_1007_s12094_015_1421_9 crossref_primary_10_1200_PO_21_00250 crossref_primary_10_1093_jjco_hyad074 crossref_primary_10_1002_pbc_29930 crossref_primary_10_3390_cancers9100138 crossref_primary_10_18632_oncotarget_13541 crossref_primary_10_1002_pbc_27995 crossref_primary_10_17650_2311_1267_2014_0_4_32_40 crossref_primary_10_1002_pbc_25698 crossref_primary_10_1016_j_critrevonc_2018_08_007 crossref_primary_10_1007_s00277_017_3166_8 crossref_primary_10_1111_bjh_14009 crossref_primary_10_1016_j_yrtph_2018_05_009 crossref_primary_10_1158_1078_0432_CCR_14_2024 crossref_primary_10_1007_s00280_016_3220_6 crossref_primary_10_3389_fped_2022_910268 crossref_primary_10_1007_s11912_022_01270_8 crossref_primary_10_1016_j_ejmech_2019_111734 crossref_primary_10_1038_onc_2014_474 crossref_primary_10_1186_s40478_020_00902_z crossref_primary_10_3892_ol_2016_4157 crossref_primary_10_1016_j_hoc_2016_11_003 crossref_primary_10_1177_1093526616686445 crossref_primary_10_1016_j_hoc_2016_11_001 crossref_primary_10_1111_bjh_18953 crossref_primary_10_1200_PO_20_00383 crossref_primary_10_1007_s11899_015_0277_y crossref_primary_10_1200_PO_23_00138 crossref_primary_10_1097_PAI_0000000000000068 crossref_primary_10_2217_pgs_13_227 crossref_primary_10_1126_scisignal_aam7550 crossref_primary_10_3390_ph9020028 crossref_primary_10_1097_MPH_0000000000001907 crossref_primary_10_1158_1078_0432_CCR_18_0332 crossref_primary_10_3390_pharmaceutics16070943 crossref_primary_10_1200_PO_17_00015 crossref_primary_10_18632_oncotarget_4342 crossref_primary_10_18632_oncotarget_6527 crossref_primary_10_1002_hon_2455 crossref_primary_10_1016_j_jaapos_2016_01_009 crossref_primary_10_1158_1078_0432_CCR_14_2123 crossref_primary_10_1093_jjco_hyu069 crossref_primary_10_18632_oncotarget_14408 crossref_primary_10_3348_kjr_2017_18_1_6 crossref_primary_10_1371_journal_pone_0121378 crossref_primary_10_3390_children8060505 crossref_primary_10_1016_S1470_2045_13_70123_2 crossref_primary_10_5045_br_2014_49_4_246 crossref_primary_10_1016_j_ctrv_2015_03_005 crossref_primary_10_1101_mcs_a001115 crossref_primary_10_1097_MPH_0000000000001914 crossref_primary_10_1080_08880018_2018_1541492 |
| Cites_doi | 10.1038/onc.2011.647 10.1593/neo.81040 10.1073/pnas.1019559108 10.1182/blood.V97.12.3699 10.1038/nature05945 10.1200/JCO.2008.20.1764 10.1056/NEJMcpc1102202 10.1002/pbc.21817 10.1158/0008-5472.CAN-08-4419 10.1200/JCO.2011.37.8588 10.1126/scitranslmed.3002950 10.1038/nature07399 10.1158/0008-5472.CAN-10-4041 10.1016/S1470-2045(11)70232-7 10.1038/nature07398 10.1038/nature07261 10.1038/nature07397 10.1016/S1470-2045(12)70344-3 10.1182/blood-2007-02-066852 10.1002/cncr.27391 10.1158/1535-7163.MCT-07-0365 10.1038/nature09454 10.1200/JCO.2004.02.138 10.1200/JCO.2007.12.7712 10.1158/0008-5472.CAN-10-2956 10.1056/NEJMoa1007056 10.1200/JCO.2010.28.5999 10.1126/science.8122112 10.1016/0959-8049(94)00509-4 10.1593/neo.11222 |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited May 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited May 2013 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1016/S1470-2045(13)70095-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (ProQuest) Lancet Titles ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Oncogenes and Growth Factors Abstracts Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 480 |
| ExternalDocumentID | PMC3730818 2957799391 23598171 10_1016_S1470_2045_13_70095_0 S1470204513700950 1_s2_0_S1470204513700950 |
| Genre | Multicenter Study Clinical Trial, Phase I Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation | Pfizer and National Cancer Institute grant to the Children's Oncology Group. |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA016520 – fundername: NCI NIH HHS grantid: U10 CA098413 – fundername: NCI NIH HHS grantid: R01 CA140198 – fundername: NCI NIH HHS grantid: UM1 CA097452 – fundername: NCI NIH HHS grantid: U01 CA097452 – fundername: NCI NIH HHS grantid: U10 CA098543 – fundername: National Cancer Institute : NCI grantid: U01 CA097452 || CA |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c670t-ca95b953c851866b9b25fd22f4beb7ec1b26840b87a1248b73827fa49f99e7b83 |
| IEDL.DBID | 8C1 |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Thu Aug 21 18:26:22 EDT 2025 Fri Sep 05 06:24:13 EDT 2025 Thu Sep 04 17:13:06 EDT 2025 Fri Sep 05 04:51:09 EDT 2025 Fri Jul 25 06:33:11 EDT 2025 Mon Jul 21 06:04:27 EDT 2025 Tue Jul 01 04:04:41 EDT 2025 Thu Apr 24 23:04:22 EDT 2025 Fri Feb 23 02:29:53 EST 2024 Sun Feb 23 10:18:51 EST 2025 Tue Aug 26 19:21:15 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c670t-ca95b953c851866b9b25fd22f4beb7ec1b26840b87a1248b73827fa49f99e7b83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/3730818 |
| PMID | 23598171 |
| PQID | 1346914981 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3730818 proquest_miscellaneous_1751228220 proquest_miscellaneous_1751214862 proquest_miscellaneous_1348504153 proquest_journals_1346914981 pubmed_primary_23598171 crossref_citationtrail_10_1016_S1470_2045_13_70095_0 crossref_primary_10_1016_S1470_2045_13_70095_0 elsevier_sciencedirect_doi_10_1016_S1470_2045_13_70095_0 elsevier_clinicalkeyesjournals_1_s2_0_S1470204513700950 elsevier_clinicalkey_doi_10_1016_S1470_2045_13_70095_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-05-01 |
| PublicationDateYYYYMMDD | 2013-05-01 |
| PublicationDate_xml | – month: 05 year: 2013 text: 2013-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Mossé, Laudenslager, Longo (bib10) 2008; 455 Shaw, Forcione, Digumarthy, Iafrate (bib26) 2011; 365 Butrynski, D'Adamo, Hornick (bib27) 2010; 363 Morris, Kirstein, Valentine (bib2) 1994; 263 van Gaal, Flucke, Roeffen (bib14) 2012; 30 Carpenter, Haglund, Mace (bib1) 2012; 31 George, Sanda, Hanna (bib8) 2008; 455 Christensen, Zou, Arango (bib18) 2007; 6 Le Deley, Rosolen, Williams (bib25) 2010; 28 Chen, Takita, Choi (bib7) 2008; 455 Grzelinski, Steinberg, Martens, Czubayko, Lamszus, Aigner (bib13) 2009; 11 Damm-Welk, Busch, Burkhardt (bib20) 2007; 110 Soda, Choi, Enomoto (bib5) 2007; 448 Janoueix-Lerosey, Lequin, Brugières (bib9) 2008; 455 Sugawara, Togashi, Kuroda (bib6) 2012; 118 Skolnik, Barrett, Jayaraman, Patel, Adamson (bib19) 2008; 26 Shaw, Yeap, Solomon (bib15) 2011; 12 Bresler, Wood, Haglund (bib17) 2011; 3 Camidge, Bang, Kwak (bib16) 2012; 13 Passoni, Longo, Collini (bib29) 2009; 69 Griffin, Hawkins, Dvorak, Henkle, Ellingham, Perlman (bib4) 1999; 59 Murugan, Xing (bib12) 2011; 71 Anderson, Adamson, Weiner, McCabe, Smith (bib31) 2004; 22 Ady, Zucker, Asselain (bib21) 1995; 31A Katayama, Khan, Benes (bib3) 2011; 108 Seidemann, Tiemann, Schrappe (bib22) 2001; 97 Lowe, Sposto, Perkins (bib24) 2009; 52 Wang, Tu, Lin, Lin, Ko, Jou (bib11) 2011; 13 Brugières, Pacquement, Le Deley (bib23) 2009; 27 Sasaki, Okuda, Zheng (bib28) 2010; 70 Wang (10.1016/S1470-2045(13)70095-0_bib11) 2011; 13 Ady (10.1016/S1470-2045(13)70095-0_bib21) 1995; 31A Butrynski (10.1016/S1470-2045(13)70095-0_bib27) 2010; 363 Shaw (10.1016/S1470-2045(13)70095-0_bib15) 2011; 12 Soda (10.1016/S1470-2045(13)70095-0_bib5) 2007; 448 Seidemann (10.1016/S1470-2045(13)70095-0_bib22) 2001; 97 Chen (10.1016/S1470-2045(13)70095-0_bib7) 2008; 455 Camidge (10.1016/S1470-2045(13)70095-0_bib16) 2012; 13 Janoueix-Lerosey (10.1016/S1470-2045(13)70095-0_bib9) 2008; 455 Anderson (10.1016/S1470-2045(13)70095-0_bib31) 2004; 22 Griffin (10.1016/S1470-2045(13)70095-0_bib4) 1999; 59 Passoni (10.1016/S1470-2045(13)70095-0_bib29) 2009; 69 Damm-Welk (10.1016/S1470-2045(13)70095-0_bib20) 2007; 110 Christensen (10.1016/S1470-2045(13)70095-0_bib18) 2007; 6 Skolnik (10.1016/S1470-2045(13)70095-0_bib19) 2008; 26 Bollag (10.1016/S1470-2045(13)70095-0_bib30) 2010; 467 Shaw (10.1016/S1470-2045(13)70095-0_bib26) 2011; 365 Mossé (10.1016/S1470-2045(13)70095-0_bib10) 2008; 455 Morris (10.1016/S1470-2045(13)70095-0_bib2) 1994; 263 Carpenter (10.1016/S1470-2045(13)70095-0_bib1) 2012; 31 Sasaki (10.1016/S1470-2045(13)70095-0_bib28) 2010; 70 Murugan (10.1016/S1470-2045(13)70095-0_bib12) 2011; 71 Bresler (10.1016/S1470-2045(13)70095-0_bib17) 2011; 3 Brugières (10.1016/S1470-2045(13)70095-0_bib23) 2009; 27 Le Deley (10.1016/S1470-2045(13)70095-0_bib25) 2010; 28 van Gaal (10.1016/S1470-2045(13)70095-0_bib14) 2012; 30 Sugawara (10.1016/S1470-2045(13)70095-0_bib6) 2012; 118 George (10.1016/S1470-2045(13)70095-0_bib8) 2008; 455 Lowe (10.1016/S1470-2045(13)70095-0_bib24) 2009; 52 Katayama (10.1016/S1470-2045(13)70095-0_bib3) 2011; 108 Grzelinski (10.1016/S1470-2045(13)70095-0_bib13) 2009; 11 18923525 - Nature. 2008 Oct 16;455(7215):975-8 18923524 - Nature. 2008 Oct 16;455(7215):971-4 18089725 - Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 21030459 - Cancer Res. 2010 Dec 15;70(24):10038-43 19723661 - Cancer Res. 2009 Sep 15;69(18):7338-46 17392503 - Blood. 2007 Jul 15;110(2):670-7 17625570 - Nature. 2007 Aug 2;448(7153):561-6 22184391 - J Clin Oncol. 2012 Jan 20;30(3):308-15 19738127 - J Clin Oncol. 2009 Oct 20;27(30):5056-61 18724359 - Nature. 2008 Oct 16;455(7215):930-5 18182661 - J Clin Oncol. 2008 Jan 10;26(2):190-5 18985718 - Pediatr Blood Cancer. 2009 Mar;52(3):335-9 11389005 - Blood. 2001 Jun 15;97(12):3699-706 23598173 - Lancet Oncol. 2013 May;14(6):439-40 10383129 - Cancer Res. 1999 Jun 15;59(12):2776-80 21596819 - Cancer Res. 2011 Jul 1;71(13):4403-11 8122112 - Science. 1994 Mar 4;263(5151):1281-4 7718334 - Eur J Cancer. 1995;31A(2):256-61 19177199 - Neoplasia. 2009 Feb;11(2):145-56 21502504 - Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40 22072639 - Sci Transl Med. 2011 Nov 9;3(108):108ra114 15570088 - J Clin Oncol. 2004 Dec 1;22(23):4846-50 18923523 - Nature. 2008 Oct 16;455(7215):967-70 22954507 - Lancet Oncol. 2012 Oct;13(10):1011-9 21933749 - Lancet Oncol. 2011 Oct;12(11):1004-12 22266870 - Oncogene. 2012 Nov 15;31(46):4859-67 20823850 - Nature. 2010 Sep 30;467(7315):596-9 20979472 - N Engl J Med. 2010 Oct 28;363(18):1727-33 21847362 - Neoplasia. 2011 Aug;13(8):704-15 21751909 - N Engl J Med. 2011 Jul 14;365(2):158-67 20679620 - J Clin Oncol. 2010 Sep 1;28(25):3987-93 22252991 - Cancer. 2012 Sep 15;118(18):4427-36 |
| References_xml | – volume: 27 start-page: 5056 year: 2009 end-page: 5061 ident: bib23 article-title: Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology publication-title: J Clin Oncol – volume: 455 start-page: 975 year: 2008 end-page: 978 ident: bib8 article-title: Activating mutations in ALK provide a therapeutic target in neuroblastoma publication-title: Nature – volume: 22 start-page: 4846 year: 2004 end-page: 4850 ident: bib31 article-title: Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives publication-title: J Clin Oncol – volume: 110 start-page: 670 year: 2007 end-page: 677 ident: bib20 article-title: Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma publication-title: Blood – volume: 3 start-page: 108ra14 year: 2011 ident: bib17 article-title: Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma publication-title: Sci Transl Med – volume: 31A start-page: 256 year: 1995 end-page: 261 ident: bib21 article-title: A new 123I-MIBG whole body scan scoring method—application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma publication-title: Eur J Cancer – volume: 6 start-page: 3314 year: 2007 end-page: 3322 ident: bib18 article-title: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma publication-title: Mol Cancer Ther – volume: 52 start-page: 335 year: 2009 end-page: 339 ident: bib24 article-title: Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941 publication-title: Pediatr Blood Cancer – volume: 70 start-page: 10038 year: 2010 end-page: 10043 ident: bib28 article-title: The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers publication-title: Cancer Res – volume: 263 start-page: 1281 year: 1994 end-page: 1284 ident: bib2 article-title: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma publication-title: Science – volume: 448 start-page: 561 year: 2007 end-page: 566 ident: bib5 article-title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer publication-title: Nature – volume: 12 start-page: 1004 year: 2011 end-page: 1012 ident: bib15 article-title: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis publication-title: Lancet Oncol – volume: 30 start-page: 308 year: 2012 end-page: 315 ident: bib14 article-title: Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications publication-title: J Clin Oncol – volume: 31 start-page: 4859 year: 2012 end-page: 4867 ident: bib1 article-title: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma publication-title: Oncogene – volume: 28 start-page: 3987 year: 2010 end-page: 3993 ident: bib25 article-title: Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial publication-title: J Clin Oncol – volume: 59 start-page: 2776 year: 1999 end-page: 2780 ident: bib4 article-title: Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors publication-title: Cancer Res – volume: 108 start-page: 7535 year: 2011 end-page: 7540 ident: bib3 article-title: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK publication-title: Proc Natl Acad Sci USA – volume: 118 start-page: 4427 year: 2012 end-page: 4436 ident: bib6 article-title: Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method publication-title: Cancer – volume: 365 start-page: 158 year: 2011 end-page: 167 ident: bib26 article-title: Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung publication-title: N Engl J Med – volume: 71 start-page: 4403 year: 2011 end-page: 4411 ident: bib12 article-title: Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene publication-title: Cancer Res – volume: 11 start-page: 145 year: 2009 end-page: 156 ident: bib13 article-title: Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK publication-title: Neoplasia – volume: 26 start-page: 190 year: 2008 end-page: 195 ident: bib19 article-title: Shortening the timeline of pediatric phase I trials: the rolling six design publication-title: J Clin Oncol – volume: 97 start-page: 3699 year: 2001 end-page: 3706 ident: bib22 article-title: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90 publication-title: Blood – volume: 455 start-page: 971 year: 2008 end-page: 974 ident: bib7 article-title: Oncogenic mutations of ALK kinase in neuroblastoma publication-title: Nature – volume: 13 start-page: 1011 year: 2012 end-page: 1019 ident: bib16 article-title: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study publication-title: Lancet Oncol – volume: 13 start-page: 704 year: 2011 end-page: 715 ident: bib11 article-title: Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer publication-title: Neoplasia – volume: 363 start-page: 1727 year: 2010 end-page: 1733 ident: bib27 article-title: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor publication-title: N Engl J Med – volume: 69 start-page: 7338 year: 2009 end-page: 7346 ident: bib29 article-title: Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients publication-title: Cancer Res – volume: 455 start-page: 930 year: 2008 end-page: 935 ident: bib10 article-title: Identification of ALK as a major familial neuroblastoma predisposition gene publication-title: Nature – volume: 455 start-page: 967 year: 2008 end-page: 970 ident: bib9 article-title: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma publication-title: Nature – volume: 31 start-page: 4859 year: 2012 ident: 10.1016/S1470-2045(13)70095-0_bib1 article-title: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma publication-title: Oncogene doi: 10.1038/onc.2011.647 – volume: 11 start-page: 145 year: 2009 ident: 10.1016/S1470-2045(13)70095-0_bib13 article-title: Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK publication-title: Neoplasia doi: 10.1593/neo.81040 – volume: 108 start-page: 7535 year: 2011 ident: 10.1016/S1470-2045(13)70095-0_bib3 article-title: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1019559108 – volume: 97 start-page: 3699 year: 2001 ident: 10.1016/S1470-2045(13)70095-0_bib22 article-title: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90 publication-title: Blood doi: 10.1182/blood.V97.12.3699 – volume: 448 start-page: 561 year: 2007 ident: 10.1016/S1470-2045(13)70095-0_bib5 article-title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer publication-title: Nature doi: 10.1038/nature05945 – volume: 27 start-page: 5056 year: 2009 ident: 10.1016/S1470-2045(13)70095-0_bib23 article-title: Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.1764 – volume: 365 start-page: 158 year: 2011 ident: 10.1016/S1470-2045(13)70095-0_bib26 article-title: Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung publication-title: N Engl J Med doi: 10.1056/NEJMcpc1102202 – volume: 52 start-page: 335 year: 2009 ident: 10.1016/S1470-2045(13)70095-0_bib24 article-title: Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.21817 – volume: 69 start-page: 7338 year: 2009 ident: 10.1016/S1470-2045(13)70095-0_bib29 article-title: Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-4419 – volume: 30 start-page: 308 year: 2012 ident: 10.1016/S1470-2045(13)70095-0_bib14 article-title: Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications publication-title: J Clin Oncol doi: 10.1200/JCO.2011.37.8588 – volume: 3 start-page: 108ra14 year: 2011 ident: 10.1016/S1470-2045(13)70095-0_bib17 article-title: Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002950 – volume: 455 start-page: 971 year: 2008 ident: 10.1016/S1470-2045(13)70095-0_bib7 article-title: Oncogenic mutations of ALK kinase in neuroblastoma publication-title: Nature doi: 10.1038/nature07399 – volume: 71 start-page: 4403 year: 2011 ident: 10.1016/S1470-2045(13)70095-0_bib12 article-title: Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-4041 – volume: 12 start-page: 1004 year: 2011 ident: 10.1016/S1470-2045(13)70095-0_bib15 article-title: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70232-7 – volume: 455 start-page: 967 year: 2008 ident: 10.1016/S1470-2045(13)70095-0_bib9 article-title: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma publication-title: Nature doi: 10.1038/nature07398 – volume: 455 start-page: 930 year: 2008 ident: 10.1016/S1470-2045(13)70095-0_bib10 article-title: Identification of ALK as a major familial neuroblastoma predisposition gene publication-title: Nature doi: 10.1038/nature07261 – volume: 455 start-page: 975 year: 2008 ident: 10.1016/S1470-2045(13)70095-0_bib8 article-title: Activating mutations in ALK provide a therapeutic target in neuroblastoma publication-title: Nature doi: 10.1038/nature07397 – volume: 13 start-page: 1011 year: 2012 ident: 10.1016/S1470-2045(13)70095-0_bib16 article-title: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70344-3 – volume: 110 start-page: 670 year: 2007 ident: 10.1016/S1470-2045(13)70095-0_bib20 article-title: Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma publication-title: Blood doi: 10.1182/blood-2007-02-066852 – volume: 118 start-page: 4427 year: 2012 ident: 10.1016/S1470-2045(13)70095-0_bib6 article-title: Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method publication-title: Cancer doi: 10.1002/cncr.27391 – volume: 6 start-page: 3314 year: 2007 ident: 10.1016/S1470-2045(13)70095-0_bib18 article-title: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-07-0365 – volume: 467 start-page: 596 year: 2010 ident: 10.1016/S1470-2045(13)70095-0_bib30 article-title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma publication-title: Nature doi: 10.1038/nature09454 – volume: 22 start-page: 4846 year: 2004 ident: 10.1016/S1470-2045(13)70095-0_bib31 article-title: Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives publication-title: J Clin Oncol doi: 10.1200/JCO.2004.02.138 – volume: 26 start-page: 190 year: 2008 ident: 10.1016/S1470-2045(13)70095-0_bib19 article-title: Shortening the timeline of pediatric phase I trials: the rolling six design publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.7712 – volume: 70 start-page: 10038 year: 2010 ident: 10.1016/S1470-2045(13)70095-0_bib28 article-title: The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2956 – volume: 59 start-page: 2776 year: 1999 ident: 10.1016/S1470-2045(13)70095-0_bib4 article-title: Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors publication-title: Cancer Res – volume: 363 start-page: 1727 year: 2010 ident: 10.1016/S1470-2045(13)70095-0_bib27 article-title: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor publication-title: N Engl J Med doi: 10.1056/NEJMoa1007056 – volume: 28 start-page: 3987 year: 2010 ident: 10.1016/S1470-2045(13)70095-0_bib25 article-title: Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial publication-title: J Clin Oncol doi: 10.1200/JCO.2010.28.5999 – volume: 263 start-page: 1281 year: 1994 ident: 10.1016/S1470-2045(13)70095-0_bib2 article-title: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma publication-title: Science doi: 10.1126/science.8122112 – volume: 31A start-page: 256 year: 1995 ident: 10.1016/S1470-2045(13)70095-0_bib21 article-title: A new 123I-MIBG whole body scan scoring method—application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma publication-title: Eur J Cancer doi: 10.1016/0959-8049(94)00509-4 – volume: 13 start-page: 704 year: 2011 ident: 10.1016/S1470-2045(13)70095-0_bib11 article-title: Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer publication-title: Neoplasia doi: 10.1593/neo.11222 – reference: 18724359 - Nature. 2008 Oct 16;455(7215):930-5 – reference: 20679620 - J Clin Oncol. 2010 Sep 1;28(25):3987-93 – reference: 22266870 - Oncogene. 2012 Nov 15;31(46):4859-67 – reference: 21933749 - Lancet Oncol. 2011 Oct;12(11):1004-12 – reference: 19723661 - Cancer Res. 2009 Sep 15;69(18):7338-46 – reference: 21751909 - N Engl J Med. 2011 Jul 14;365(2):158-67 – reference: 17392503 - Blood. 2007 Jul 15;110(2):670-7 – reference: 19177199 - Neoplasia. 2009 Feb;11(2):145-56 – reference: 21847362 - Neoplasia. 2011 Aug;13(8):704-15 – reference: 22954507 - Lancet Oncol. 2012 Oct;13(10):1011-9 – reference: 15570088 - J Clin Oncol. 2004 Dec 1;22(23):4846-50 – reference: 21596819 - Cancer Res. 2011 Jul 1;71(13):4403-11 – reference: 19738127 - J Clin Oncol. 2009 Oct 20;27(30):5056-61 – reference: 23598173 - Lancet Oncol. 2013 May;14(6):439-40 – reference: 8122112 - Science. 1994 Mar 4;263(5151):1281-4 – reference: 18923525 - Nature. 2008 Oct 16;455(7215):975-8 – reference: 18985718 - Pediatr Blood Cancer. 2009 Mar;52(3):335-9 – reference: 20823850 - Nature. 2010 Sep 30;467(7315):596-9 – reference: 21030459 - Cancer Res. 2010 Dec 15;70(24):10038-43 – reference: 11389005 - Blood. 2001 Jun 15;97(12):3699-706 – reference: 18089725 - Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 – reference: 20979472 - N Engl J Med. 2010 Oct 28;363(18):1727-33 – reference: 22072639 - Sci Transl Med. 2011 Nov 9;3(108):108ra114 – reference: 7718334 - Eur J Cancer. 1995;31A(2):256-61 – reference: 18923524 - Nature. 2008 Oct 16;455(7215):971-4 – reference: 10383129 - Cancer Res. 1999 Jun 15;59(12):2776-80 – reference: 21502504 - Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40 – reference: 18923523 - Nature. 2008 Oct 16;455(7215):967-70 – reference: 17625570 - Nature. 2007 Aug 2;448(7153):561-6 – reference: 22184391 - J Clin Oncol. 2012 Jan 20;30(3):308-15 – reference: 18182661 - J Clin Oncol. 2008 Jan 10;26(2):190-5 – reference: 22252991 - Cancer. 2012 Sep 15;118(18):4427-36 |
| SSID | ssj0017105 |
| Score | 2.6033602 |
| Snippet | Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory... Summary Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma,... Various human cancers haveALKgene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic... Background: Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 472 |
| SubjectTerms | Adolescent Age Factors Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Bone marrow Cancer therapies Chemotherapy Child Child, Preschool Children & youth Consortia Disease Progression Drug Administration Schedule Drug Resistance, Neoplasm - genetics Female Hematology Hematology, Oncology and Palliative Medicine Hemoglobin Humans Infant Kinases Lymphoma Lymphoma, Large-Cell, Anaplastic - drug therapy Lymphoma, Large-Cell, Anaplastic - enzymology Lymphoma, Large-Cell, Anaplastic - genetics Lymphoma, Large-Cell, Anaplastic - pathology Male Maximum Tolerated Dose Molecular Targeted Therapy Mutation Neoplasms - drug therapy Neoplasms - enzymology Neoplasms - genetics Neoplasms - pathology Neuroblastoma Neutrophils Oncology Patients Pediatrics Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - pharmacokinetics Pyrazoles - therapeutic use Pyridines - adverse effects Pyridines - pharmacokinetics Pyridines - therapeutic use Radiation Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - genetics Receptor Protein-Tyrosine Kinases - metabolism Time Factors Toxicity Treatment Outcome Tumors Young Adult |
| Title | Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204513700950 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204513700950 https://dx.doi.org/10.1016/S1470-2045(13)70095-0 https://www.ncbi.nlm.nih.gov/pubmed/23598171 https://www.proquest.com/docview/1346914981 https://www.proquest.com/docview/1348504153 https://www.proquest.com/docview/1751214862 https://www.proquest.com/docview/1751228220 https://pubmed.ncbi.nlm.nih.gov/PMC3730818 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZoKyEuiDeFshokJOAQuk6cOOGCYNWqQmpBlEp7s2zHUVfaTZYme1j-FH-RGedRyqPLNfHIiWc8_jwef8PYi0xYhB1GB5GNXCByNGPj5DjIQplyikJaRwH945Pk6Ex8nMbTLuBWd2mVvU_0jjqvLMXI93mEGzmE8yl_t_wWUNUoOl3tSmhssR2OPpgmZjoZUjy4bFMYucDOiXb98gbP_unw8BWPXktCGsH4X2vTn9jz9xTKX9akwzvsdgcm4X2r_bvshivvsZvH3XH5ffbjVBeuWYMuc6ALDFQnAqoC0FN8r5pZOTOAmBWWuq_XAR3Nag0UnwX8wgtfj2cNaKKzHJrVAvusAYV0qZeIvLFnmFM2eUBHADBfo3VUC_0WNEy6e-Iva_hUenLsNfhQFyzPce0EDrgXrxH-z1YL8DS3D9jZ4cHXyVHQVWgIbCLHTWB1FpssjizitjRJTGbCuMjDsBDGGeksN55MxqRSI45IjYzSUBZaZEWWOWnS6CHbLqvSPWYgRGHjBB-h8QgrhZaFzRNZZM4Y9DvjXSZ63Sjb0ZdTFY25GvLUSKWKVKp4pLxKFYq9GcSWLX_HJoGkV7zqL6eiO1W4wmwSlH8TdHXnFGrFVR2qcStNwjzyoiiZDpId7mnxzP90utfbprrsZ5gqu-z58BrdBhmCLl218m3SmOgZomvaSESDuF1Owg1tKBUZP-VROyWGcQ6JHRInIY7MlckyNCBq86tvytm5pziPcOFBKPnk-t97ym6FvjoJ5Z_use3mYuWeIUZszIhtyakceXcwYjsfDk4-f_kJmUpk1w |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2hwCCBgEPoJk7iBAkhtFBtabcc2kq9ubbjqCvtZpcmK7T8KPiLzDiPUh5dLr0m_uIkM575bI9nGHuWhgZph1YeN9x6YYZqrK3oeWkgEp9WIY2lBf3hbjw4CD8dRocr7Ht7FobCKlub6Ax1NjW0Rr7hc5zIIZ1P_HezLx5VjaLd1baERq0W23bxFads5dutDyjf50Gw-XG_P_CaqgKeiUWv8oxKI51G3CDXSOJYpzqI8iwI8lBbLazxtUuAohOh0PclWvAkELkK0zxNrdAJx-deYpdDzmMKIUv6XUiJL-qQST_Ej6U076cnhjb2uosvff5KELPxev_yhX9y3d9DNn_xgZs32PWGvML7WttushVb3GJXhs32_G32Y0_ltlqAKjKgAxNUlwKmOaBl-jatRsVIA3JkmKm2Pgg0aV1LoPVgwDc8cfV_FoBDYpRBNZ9gnyUgSBVqhkwfe4YxRa97tOUA4wVq43Si3oCCfnMu_UUJnwuXjHsBbmkNZsfoq8EHnPuXON0YzSfg0ureYQcXIru7bLWYFvY-gzDMTRTjJVTW0IhQidxkschTqzXaud4aC1vZSNOkS6eqHWPZxcWRSCWJVPpcOpFKhL3uYLM6X8gyQNwKXraHYdF8S_Roy4Dib0BbNkaolL4sA9mr0QT2uYMiMumQDc-q-dP_dLre6qY87acbmmvsaXcbzRQpgirsdO7aJBGlg-DntBHIPnF6HgdL2lDoM77KvXpIdP85oGyUOAjxz5wZLF0DSqV-9k4xOnYp1Tk6OqSuD87_vCfs6mB_uCN3tna3H7JrgauMQrGv62y1OpnbR8hPK_3YGQVgRxdthX4CT46e8g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJ028IO4MBhwkEPAQ2jgXJ0gTgm3VxliZ2CbtzdiOo1Vqk7KkQuVP8T_4VRy7Tsa4rLzsNfGpU5-r7XO-Q8jTNFQYdkjhBSrQXpihGEvNel5KWeKbU0ilzYH-3iDePgrfH0fHS-RHUwtj0iobm2gNdVYqc0be9QPcyGE4n_jd3KVF7G_230y-eKaDlLlpbdppCNdmIVu3cGOuyGNXz77idq5a39lE3j-jtL91uLHtuY4DnopZr_aUSCOZRoHCOCSJY5lKGuUZpXkotWRa-dKCo8iECfSLiWRBQlkuwjRPU81kEuDvXiHLDL0k7ZDld1uD_U_tnQabJ1T6IS6FAYE_qyfqHrQPX_jBS2biHq_3L0_5ZyT8e0LnLx6yf51cc6EtvJ3L4g2ypIubZGXPXd7fIt8PRK7rGYgiA1NOYbpWQJkD2q1vZT0shhIwgoaJaLqHgAN9rcCcFgN-4antDjQDVJhhBvV0jHNWgESiEBPcB-DMMDK57Z65kIDRDGW1HIvXIGDDVa0_r-BjYaG6Z2AP3mBygp4cfFCogLgZGU7HYEF3b5OjS-HeHdIpykLfIxCGuYpifISiHCoWCparLGZ5qqVEK9hbJWHDG64cmLrp6THibdacYSk3LOV-wC1LOZK9askmczSRRQRxw3jelMqicefo7xYRsr8R6sqZqIr7vKK8N6c2xH5gSZEyaSldFDaPrv5n0rVGNvnZPK3irpIn7Ws0YkYQRKHLqR2TRAYsIrhgDMPYFDfvMV0wxiRG46fcnatEu87UYFWiEuLKnFOWdoABWj__phieWMD1AN0gBrb3L_57j8kKWiT-YWew-4BcpbZtikmMXSOd-nSqH2LwWstHzioA-XzZhugn6ROp6Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+activity+of+crizotinib+for+paediatric+patients+with+refractory+solid+tumours+or+anaplastic+large-cell+lymphoma%3A+a+Children%27s+Oncology+Group+phase+1+consortium+study&rft.jtitle=The+lancet+oncology&rft.au=Moss%C3%A9%2C+Yael+P%2C+Dr&rft.au=Lim%2C+Megan+S%2C+MD&rft.au=Voss%2C+Stephan+D%2C+MD&rft.au=Wilner%2C+Keith%2C+PhD&rft.date=2013-05-01&rft.issn=1470-2045&rft.volume=14&rft.issue=6&rft.spage=472&rft.epage=480&rft_id=info:doi/10.1016%2FS1470-2045%2813%2970095-0&rft.externalDBID=ECK1-s2.0-S1470204513700950&rft.externalDocID=1_s2_0_S1470204513700950 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204513X71517%2Fcov150h.gif |